CO4290299A1 - Derivados de 1,5-benzodiazepina - Google Patents

Derivados de 1,5-benzodiazepina

Info

Publication number
CO4290299A1
CO4290299A1 CO94031454A CO94031454A CO4290299A1 CO 4290299 A1 CO4290299 A1 CO 4290299A1 CO 94031454 A CO94031454 A CO 94031454A CO 94031454 A CO94031454 A CO 94031454A CO 4290299 A1 CO4290299 A1 CO 4290299A1
Authority
CO
Colombia
Prior art keywords
atoms
carbon
rent
replaced
hydroxy
Prior art date
Application number
CO94031454A
Other languages
English (en)
Inventor
Daniele Donati
Antonella Ursini
Mauro Corsi
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of CO4290299A1 publication Critical patent/CO4290299A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

REIVINDICACION NUMERO LOS COMPUESTOS DE LA FORMULA GENERAL (I) FIGURA 1 CARACTERIZADO PORQUE: R1 REPRESENTA UN GRUPO FENILO, CICLOALQUILO CON 3 A 7 ATOMOS DE CARBONO, CICLOALQUILO CON 7 A 11 A- TOMOS DE CARBONO, UNIDO POR MEDIO DE UN PUENTE O ALQUILO CON 1 A 6 ATOMOS DE CARBONO, TAL GRUPO PUEDE ESTAR SUSTITUIDO POR UN HIDROXI, FENILO, AL- COXICARBONILO CON 1 A 6 ATOMOS DE CARBONO, CICLO- ALQUILO CON 3 A 7 ATOMOS DE CARBONO, O CICLOALQUI- LO CON 7 A 11 ATOMOS DE CARBONO, UNIDO POR MEDIO DE UN PUENTE; R2 REPRESENTA UN GRUPO FENILO OPCIONALMENTE SUSTI- TITUIDO POR 1 O 2 SUSTITUYENTES SELECCIONADOS DE, HALOGENO, ALQUILO CON 1 A 4 ATOMOS DE CARBONO, AL- QUILTIO CON 1 A 4 ATOMOS DE CARBONO, CIANO, NITRO, TRIFLUOROMETILO, TRIFLUOROMETOXI, (CH2)nR4 u O(CH2)pR4 EN DONDE REPRESENTA HIDROXI, ALCOXI CON 1 A 4 ATOMOS DE CARBONO, CO2R5 O NR6R7; n ES CERO O 1; p ES UN NUMERO ENTERO DESDE 1 HASTA 4; R3 RE- PRESENTA EL GRUPO AlqNR8R9; R5 REPRESENTA HIDROGENO O ALQUILO CON 1 A 4 ATOMOS DE CARBONO; R6 REPRESENTA HIDROGENO O ALQUILO CON 1 A 4 ATOMOS DE CARBONO; R7 REPRESENTA HIDROGENO, ALQUILO CON 1 A 4 ATOMOS DE CARBONO, ACILO, O ALQUILO CON 2 A 6 ATOMOS DE CARBONO, SUSTITUIDO POR UNO O MAS GRUPOS HIDROXI, CARBOXILO Y/O AMINO O R6 Y R7 JUNTO CON EL ATOMO DE NITROGENO AL CUAL LOS MISMOS ESTAN UNIDOS, FOR- MAN UN ANILLO HETEROCICLICO SATURADO CON 5-7 ELE- MENTOS, EL CUAL CONTIENEN UN HETEROATOMO ADICIONAL SELECCIONADO DE OXIGENO, AZUGRE O NITROGENO Y/O PUEDE ESTAR SUSTITUIDO POR 1 O 2 GRUPOS HIDROXI O ALQUILO CON 1 A 4 ATOMOS DE CARBONO; R8 Y R9 REPRESENTAN INDEPENDIENTEMENTE HIDROGENO, ALQUILO CON 1 A 4 ATOMOS DE CARBONO O ALQUILO CON 2 A 6 ATOMOS DE CARBONO, SUSTITUIDOS POR UNO O MAS GRUPOS HIDROXI, CARBOXILO Y/O AMINO O R8 Y R9 JUN- TO CON EL ATOMO DE NITROGENO EL CUAL LOS MISMOS ESTAN UNIDOS, REPRESENTAN UN ANILLO HETEROCICLICO SATURADO CON 5-7 ELEMENTOS, EL CUAL PUEDE CONTENER UN HETEROATOMO ADICIONAL SELECCIONADO DE OXIGENO, AZUFRE O NITROGENO Y/O PUEDE ESTAR SUSTITUIDO POR 1 O 2 GRUPOS HIDROXI O ALQUILO CON 1 A 4 ATOMOS DE CARBONO; Alq REPRESENTA UNA CADENA DE ALQUILENO CON 2 A 6 ATOMOS DE CARBONO, RECTAO RAMIFICADA, SUSTITUIDA OPCIONALMENTE POR UN GRUPO HIDROXILO; R10 REPRESENTA HIDROGENO O UN ATOMO DE HALOGENO, m ES CERO, 1 O 2; X ES OXIGENO O NH; Y SALES ACEPTABLES FARMACEUTI- CAMENTE Y/O ESTERES METABOLICAMENTE LABILES DE LOS MISMOS".
CO94031454A 1993-07-20 1994-07-18 Derivados de 1,5-benzodiazepina CO4290299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939314981A GB9314981D0 (en) 1993-07-20 1993-07-20 Chemical compounds

Publications (1)

Publication Number Publication Date
CO4290299A1 true CO4290299A1 (es) 1996-04-17

Family

ID=10739096

Family Applications (1)

Application Number Title Priority Date Filing Date
CO94031454A CO4290299A1 (es) 1993-07-20 1994-07-18 Derivados de 1,5-benzodiazepina

Country Status (32)

Country Link
US (1) US5716953A (es)
EP (1) EP0710230B1 (es)
JP (1) JP3587849B2 (es)
KR (1) KR100347287B1 (es)
CN (1) CN1050835C (es)
AP (1) AP492A (es)
AT (1) ATE171167T1 (es)
AU (1) AU687858B2 (es)
CA (1) CA2167308A1 (es)
CO (1) CO4290299A1 (es)
CZ (1) CZ290472B6 (es)
DE (1) DE69413405T2 (es)
DK (1) DK0710230T3 (es)
EC (1) ECSP941120A (es)
ES (1) ES2123812T3 (es)
FI (1) FI960223A (es)
GB (1) GB9314981D0 (es)
HR (1) HRP940411B1 (es)
HU (1) HU222439B1 (es)
IL (1) IL110366A (es)
IS (1) IS4190A (es)
MY (1) MY118638A (es)
NO (1) NO313288B1 (es)
NZ (1) NZ271075A (es)
PE (1) PE8295A1 (es)
PL (1) PL175609B1 (es)
RU (1) RU2135485C1 (es)
SI (1) SI0710230T1 (es)
SV (1) SV1994000031A (es)
TW (1) TW290542B (es)
WO (1) WO1995003285A1 (es)
ZA (1) ZA945238B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
AU3459497A (en) * 1996-07-12 1998-02-09 Chugai Seiyaku Kabushiki Kaisha Cancer cell proliferation inhibitors
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6569851B1 (en) * 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DK1224175T3 (da) * 1999-10-15 2004-07-12 Hoffmann La Roche Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
US8430925B2 (en) * 2004-02-27 2013-04-30 Cardiacmd, Inc. Prosthetic heart valves, scaffolding structures, and systems and methods for implantation of same
CN101657432B (zh) * 2007-04-19 2013-04-10 弗·哈夫曼-拉罗切有限公司 二氢-苯并[b][1,4]二氮杂*-2-酮磺酰胺衍生物
RU2540464C2 (ru) * 2012-05-28 2015-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Водорастворимое производное амида салициловой кислоты, обладающее транквилизирующей, ноотропной и анальгезирующей активностью
CN103435562B (zh) * 2013-08-26 2016-02-24 华东理工大学 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
RU2702359C1 (ru) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения 2,2,4-триалкил-2,3-дигидро-1Н-1,5-бензодиазепинов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641280B1 (fr) * 1988-12-29 1994-01-21 Roussel Uclaf Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments
CA2068355A1 (en) * 1991-05-14 1992-11-15 Mark S. Chambers Benzodiazephine derivatives, compositions containing them and their use in therapy
GEP20001968B (en) * 1992-01-21 2000-03-05 Glaxo Spa Arilthio Compounds as Antibacterial and Antiviral Agents
GB9201181D0 (en) * 1992-01-21 1992-03-11 Glaxo Spa Chemical compounds
GB9225492D0 (en) * 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives

Also Published As

Publication number Publication date
TW290542B (es) 1996-11-11
ZA945238B (en) 1995-02-09
CA2167308A1 (en) 1995-02-02
CN1138853A (zh) 1996-12-25
CZ290472B6 (cs) 2002-07-17
HU9600124D0 (en) 1996-03-28
FI960223A (fi) 1996-03-19
CN1050835C (zh) 2000-03-29
IS4190A (is) 1995-01-21
SI0710230T1 (en) 1999-02-28
HU222439B1 (hu) 2003-07-28
ES2123812T3 (es) 1999-01-16
ECSP941120A (es) 1995-01-16
EP0710230A1 (en) 1996-05-08
IL110366A (en) 1999-01-26
PE8295A1 (es) 1995-04-20
DK0710230T3 (da) 1999-06-14
IL110366A0 (en) 1994-10-21
HRP940411A2 (en) 1997-04-30
AP9400657A0 (en) 1994-07-31
MY118638A (en) 2004-12-31
KR100347287B1 (ko) 2002-12-06
JP3587849B2 (ja) 2004-11-10
HUT73499A (en) 1996-08-28
AP492A (en) 1996-05-13
CZ17396A3 (en) 1996-07-17
DE69413405D1 (de) 1998-10-22
ATE171167T1 (de) 1998-10-15
PL312659A1 (en) 1996-04-29
JPH09502428A (ja) 1997-03-11
NO960237D0 (no) 1996-01-19
HRP940411B1 (en) 2000-12-31
DE69413405T2 (de) 1999-04-15
AU687858B2 (en) 1998-03-05
RU2135485C1 (ru) 1999-08-27
EP0710230B1 (en) 1998-09-16
AU7458994A (en) 1995-02-20
FI960223A0 (fi) 1996-01-17
NO313288B1 (no) 2002-09-09
NZ271075A (en) 1998-06-26
SV1994000031A (es) 1995-10-04
PL175609B1 (pl) 1999-01-29
GB9314981D0 (en) 1993-09-01
US5716953A (en) 1998-02-10
WO1995003285A1 (en) 1995-02-02
NO960237L (no) 1996-03-19

Similar Documents

Publication Publication Date Title
CO4290299A1 (es) Derivados de 1,5-benzodiazepina
FI954105A (fi) Uusia 4-aminopyridiinejä, niiden valmistusmenetelmä sekä näitä yhdisteitä sisältäviä lääkkeitä
PA8539401A1 (es) Quinazolinas como inhibidores de mmp-13
ES2185665T3 (es) Derivados de benzofurano como antagonistas de taquicininas.
GT199600100A (es) Procedimientos para hacer compuestos heterociclicos.
PE10290A1 (es) Procedimiento de preparacion de derivados de benzotriazol
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
AU540766B2 (en) Nonapeptide and decapeptide analogs of lhrh
ES2164889T3 (es) Semicarbazonas con actividad sobre el snc y preparados farmaceuticos a base de las mismas.
ES2122275T3 (es) Derivados amidicos de la vitamina d.
CO4340623A1 (es) Derivados de indolina, metodo de preparacion y uso
ES2095942T3 (es) Derivados de bencenoacetamida inhibidores del vih.
CO4700452A1 (es) Derivados de indol
ES2156933T3 (es) Derivados triciclicos de benzazepina y benzotiazepina.
CO4370018A1 (es) Derivados de naftaleno, metodo de preparacion y uso
ES2136291T3 (es) Derivados de pirimidina.
AR010195A1 (es) Antagonistas de vasopresina de benzacepina triciclicos y procedimiento para su preparacion.
DK0445026T3 (da) Aminomethylpiperidinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem
ES2159345T3 (es) Indazolcarboxamidas.
SE8505887D0 (sv) Indoler
ES2112483T3 (es) 4-aril-4-hidroxi-tetrahidropiranos y 3-aril-3-hidroxi-tetrahidrofuranos como inhibidores de 5-lipoxigenasa.
ES2158290T3 (es) Derivados de tiazolidinona opticamente activos.
ES2145306T3 (es) Nitro-benzamidas utiles como agentes anti-arritmicos.
ES2117003T3 (es) Derivados oligopeptidicos de hipoxantina dotados de actividad inmunomoduladora, y composiciones farmaceuticas que los contienen.
ES2136667T3 (es) Compuestos de etinil-alanina-amino-diol que tienen un grupo terminado en piperazinilo o un grupo terminado en piperazinil-alquilamino para el tratamiento de la hipertension.